BioWorld

March 25, 2008

Zogenix Eyes Public Markets, Files for Potential $86M IPO

Only days after the FDA accepted for review Zogenix Inc.'s new drug application for its needle-free sumatriptan candidate, the San Diego-based firm filed for an initial public offering. (BioWorld Today) Read More

Cytokinetics Sees Shares Rise on Positive Heart Drug Data

Parkinson's Treated with SCNT as Genomics Data Find Home

NewCo News: Influmedix Plans to Go Multiple Rounds With M Channel Target

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...